MARVELD2 and glioma: While the changes observed here are relative to healthy and non-glioma controls, the significantly high expression of TRiC components, CCT2 and CCT7, within plasma-EVs of GBM/GIV patients, not observed for less aggressive glioma subtypes, might therefore relate to primary GBM biology (IDH-wt) and disease severity.